Ask AI
ProCE Banner Activity

Expert Reflections on Bridging Therapy Before CAR T-Cell in MM: Key Updates From ASH 2025

Clinical Thought

Review this ClinicalThought commentary where experts in CAR T-cell therapy for MM discuss ASH 2025 updates that further define how bridging therapy influences safety and clinical outcomes with CAR T-cell therapy.

Released: February 09, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Johnson & Johnson.

Johnson & Johnson

Target Audience

This activity has been designed to meet the educational needs of hematologists/oncologists and other healthcare professionals caring for patients with multiple myeloma who are likely to benefit from bridging therapy prior to CAR T-cell treatment. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the challenges of access to and manufacturing of CAR T-cell therapy and role of bridging therapeutic strategies in patients with multiple myeloma 

  • Identify patients with multiple myeloma who are likely to benefit from bridging therapy prior to CAR T-cell treatment

  • Select optimal regimens, duration, and timing for bridging therapy for patients with multiple myeloma receiving CAR T-cell therapy based on expert guidance and available clinical evidence

Disclosure

Primary Author

Krina K. Patel, MD, MSc: consultant/advisor/speaker: AbbVie, AstraZeneca, Bristol Myers Squibb, Genentech, Johnson & Johnson, Kite, Legend Biotech, Oricel, Sanofi.

Noopur Raje, MD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Caribou Biosciences, GlaxoSmithKline, Johnson & Johnson, Moderna, Pfizer, Regeneron, Sanofi.

Surbhi Sidana, MD: consultant/advisor/speaker: AbbVie, Arcellx, BiolineRx, Bristol Myers Squibb, Genentech, Janssen, Kite, Legend, Pfizer, Poseida, Regeneron, Sanofi, Takeda; researcher: AbbVie, Allogene, Bristol Myers Squibb, Janssen, Magenta, Novartis.